Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Rhea-AI Summary
Aligos Therapeutics (Nasdaq:ALGS) reported new clinical and preclinical liver disease data at the EASL Congress 2026 in Barcelona.
Phase 1 follow-up of pevifoscorvir sodium in chronic HBV showed sustained HBV DNA control on NA therapy and HBsAg declines that may enable eligibility for antisense oligonucleotide regimens.
Multiple posters also highlighted ASO ALG-170675, HDV strategies, THR-β agonist ALG-055009 and PD-1/PD-L1 inhibitor ALG-093940.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Market Reaction – ALGS
Following this news, ALGS has gained 4.34%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $5.99. This price movement has added approximately $1M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers BYSI, IGMS, ACET and ENTX show declines between -1.42% and -2.42%, while ALGS was down 0.35% pre-news. Scanner data does not flag a coordinated sector momentum move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | EASL abstracts accepted | Positive | +3.1% | Ten EASL 2026 abstracts across HBV, HDV, MASH and liver cancer pipeline. |
| May 07 | Q1 2026 earnings | Positive | +6.8% | Q1 results plus Fast Track and upbeat B-SUPREME interim data for pevifoscorvir. |
| Apr 30 | Earnings date notice | Neutral | +1.7% | Announcement of upcoming Q1 2026 financial results release date. |
| Apr 24 | Inducement option grants | Neutral | +4.4% | Nasdaq Rule 5635(c)(4) inducement stock options to new hires. |
| Apr 16 | Greater China license | Positive | +3.2% | Exclusive Amoytop license for pevifoscorvir sodium in Greater China with milestones. |
Recent news and earnings items have generally been followed by positive price reactions.
Over the last six weeks, Aligos reported multiple pipeline and financial updates. The Amoytop Greater China license on Apr 16 and subsequent inducement grants on Apr 24 both saw positive price reactions. Earnings communication around Q1 2026, including the results release on May 7 and the earnings date notice on Apr 30, also coincided with gains. The May 13 announcement that ten abstracts were accepted for EASL 2026 was similarly well received. Today’s detailed EASL data extend that same HBV-focused narrative.
Market Pulse Summary
This announcement details extensive EASL data for pevifoscorvir sodium, including sustained antiviral effects over 96 weeks and HBsAg reductions that made 40% of certain HBeAg+ participants potentially eligible for functional cure regimens. The results build on prior Fast Track status and the Amoytop regional licensing deal. Investors may watch for progression of the B‑SUPREME trial, further combination ASO data, and future quarterly filings to gauge clinical continuity and financial runway.
Key Terms
cccDNA medical
antisense oligonucleotide medical
HBsAg medical
HBeAg medical
PD-1/PD-L1 inhibitor medical
AI-generated analysis. Not financial advice.
- Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir
- Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented
40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain.
“We are pleased to present positive data, including an investigator led study of ≥24 week follow up in HBeAg+ participants with nucleos(t)ide analogs (NAs) after 96 weeks of pevifoscorvir sodium monotherapy, which further supports our belief that we are reducing the cccDNA reservoir by activating the secondary mechanism of CAM-Es. By accessing this mechanism, we are also reducing HBsAg to a level that may allow additional patients to be eligible for functional cure therapy, including the ASO ALG-170675, being developed by Aligos and partner Amoytop,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “Further, we will present data demonstrating that the combination of pevifoscorvir sodium and our antisense oligonucleotide ALG-170675 showed an additive to synergistic effects on reductions in HBV viral markers. Taken together, these data signal that pevifoscorvir sodium has the potential to not only replace NAs as the standard of care for chronic HBV infection but play a meaningful part in a functional cure regimen.”
Pevifoscorvir Sodium Post Treatment Data
Newly presented data highlight outcomes for treatment-naïve or currently not treated HBeAg+ subjects who completed 96 weeks of 300 mg pevifoscorvir sodium monotherapy, followed by ≥24 weeks of nucleos(t)ide analog (NA) monotherapy. Among HBeAg+ subjects, 9 of 10 subjects transitioned to NA monotherapy; of these, 4 (
In addition, newly presented data showed that among participants with a baseline HBsAg ≥3,000 IU/mL,
Additionally, preclinical in vitro data demonstrated that long-term treatment with ALG-001075, the active parent moiety of pevifoscorvir sodium, resulted in profound suppression of HBeAg, HBsAg and intracellular HBV RNAs which was durable after treatment withdrawal in HBV-infected HepaRG cells, suggesting a potential reduction in cccDNA level and/or transcriptional activity.
Preclinical Data
The preclinical posters showcased Aligos’ and its collaborators’ continued innovation and commitment to advancing next-generation therapies in the liver and viral spaces with presentations spanning novel approaches and mechanistic insights.
In particular, an analog of ALG-170675, a potential best-in-class antisense oligonucleotide (ASO), demonstrated an additive to synergistic effect when combined in vitro and in vivo with ALG-001075, the active parent moiety of pevifoscorvir sodium.
Additionally, in vitro data from the hepatitis delta virus (HDV) program demonstrates how the novel approach of targeting HDV replication could be a valuable addition to the current therapeutic arsenal.
Details on the presentations are as follows:
Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection
Abstract #: 588
Title: Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
Presenter: Professor Lung-Yi Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Poster Tour – Track 8 – Viral Hepatitis; Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Abstract #: 602
Title: Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Poster Tour – Track 8 – Viral Hepatitis; Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Abstract #: 586
Title: Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection
Presenter: Kha Le, PhD
Date/Time: May 27, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Abstract #: 570
Title: ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
Presenter: Yannick Debing, PhD
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology
Abstract #: 634
Title: Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments
Presenter: Professor Barbara Testoni, PhD, HDR, DR2 INSERM - Team Leader "Hepatitis Viruses and Liver pathogenesis". Université Claude Bernand Lyon 1, Inserm UMR 1350 - PaThLiv
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology
ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection
Abstract #: 587
Title: The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
Presenter: Jin Hong, PhD
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology
ALG-055009: Potential best-in-class small molecule THR-β Agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Abstract #: 184
Title: Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
Presenter: Xuan Luong, PhD
Date/Time: May 30, 2025 at 8:30am – 4:00pm CET
Session: Poster - MASLD: Experimental and pathophysiology
Preclinical
Abstract #: 606
Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Presenter: Julie Lucifora, PhD, HDR, Director of Research, INSERM, CIRI - Centre International de Recherche en Infectiologie
Date/Time: May 28, 2026 at 12:45 – 1:45pm CET; May 28, 2026 at 8:30am – 5:00pm CET
Session: Poster Tour – Track 8 – Viral Hepatitis; Viral Hepatitis: Experimental and pathophysiology
Abstract #: 610
Title: Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition
Presenter: David McGowan, MS
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology
Abstract #: 620
Title: Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer
Presenter: Heleen Roose, PhD
Date/Time: May 28, 2026 at 8:30am – 5:00pm CET
Session: Viral Hepatitis: Experimental and pathophysiology
The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials; statements about the potential benefits of pevifoscorvir sodium including its potential to replace NAs as the standard of care for chronic HBV infection and be part of a functional cure regimen, and whether the B-SUPREME study will show superiority of pevifoscorvir sodium over NAs; statements about whether pevifoscorvir sodium will be shown to reduce the cccDNA reservoir; and statements about the potential benefits of combining pevifoscorvir sodium with an ASO agent. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
